These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38780644)

  • 1. Usp14 deficiency removes α-synuclein by regulating S100A8/A9 in Parkinson's disease.
    Ding L; Lu L; Zheng S; Zhang Z; Huang X; Ma R; Zhang M; Xu Z; Chen M; Guo Z; Zhu S; Gong J; Mao H; Zhang W; Xu P
    Cell Mol Life Sci; 2024 May; 81(1):232. PubMed ID: 38780644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
    Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH
    Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
    Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
    Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cntnap4 partial deficiency exacerbates α-synuclein pathology through astrocyte-microglia C3-C3aR pathway.
    Zhang W; Ding L; Chen H; Zhang M; Ma R; Zheng S; Gong J; Zhang Z; Xu H; Xu P; Zhang Y
    Cell Death Dis; 2023 Apr; 14(4):285. PubMed ID: 37087484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
    Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
    Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease.
    Fares MB; Maco B; Oueslati A; Rockenstein E; Ninkina N; Buchman VL; Masliah E; Lashuel HA
    Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E912-21. PubMed ID: 26839406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model.
    Gan L; Vargas MR; Johnson DA; Johnson JA
    J Neurosci; 2012 Dec; 32(49):17775-87. PubMed ID: 23223297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
    Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
    J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic deletion of nitric oxide synthase 2 ameliorates Parkinson's disease pathology and neuroinflammation in a transgenic mouse model of synucleinopathy.
    Kim J; Han JY; Lee Y; Kim K; Choi YP; Chae S; Hoe HS
    Mol Brain; 2023 Jan; 16(1):7. PubMed ID: 36647152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson's disease mice.
    Karikari AA; McFleder RL; Ribechini E; Blum R; Bruttel V; Knorr S; Gehmeyr M; Volkmann J; Brotchie JM; Ahsan F; Haack B; Monoranu CM; Keber U; Yeghiazaryan R; Pagenstecher A; Heckel T; Bischler T; Wischhusen J; Koprich JB; Lutz MB; Ip CW
    Brain Behav Immun; 2022 Mar; 101():194-210. PubMed ID: 35032575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson's disease models through PKA activation.
    Chen JY; Zhu Q; Cai CZ; Luo HB; Lu JH
    Phytomedicine; 2022 Jul; 101():154125. PubMed ID: 35525236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic mild stress accelerates the progression of Parkinson's disease in A53T α-synuclein transgenic mice.
    Wu Q; Yang X; Zhang Y; Zhang L; Feng L
    Exp Neurol; 2016 Nov; 285(Pt A):61-71. PubMed ID: 27637804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of UCHL1 modulation on alpha-synuclein in PD-like models of alpha-synucleinopathy.
    Cartier AE; Ubhi K; Spencer B; Vazquez-Roque RA; Kosberg KA; Fourgeaud L; Kanayson P; Patrick C; Rockenstein E; Patrick GN; Masliah E
    PLoS One; 2012; 7(4):e34713. PubMed ID: 22514658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian.
    Mo M; Xiao Y; Huang S; Cen L; Chen X; Zhang L; Luo Q; Li S; Yang X; Lin X; Xu P
    Oncotarget; 2017 Jan; 8(1):15-28. PubMed ID: 27965467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease.
    Chen J; Mao K; Yu H; Wen Y; She H; Zhang H; Liu L; Li M; Li W; Zou F
    J Neuroinflammation; 2021 Dec; 18(1):295. PubMed ID: 34930303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
    Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
    Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.
    Bourdenx M; Dovero S; Engeln M; Bido S; Bastide MF; Dutheil N; Vollenweider I; Baud L; Piron C; Grouthier V; Boraud T; Porras G; Li Q; Baekelandt V; Scheller D; Michel A; Fernagut PO; Georges F; Courtine G; Bezard E; Dehay B
    Acta Neuropathol Commun; 2015 Jul; 3():46. PubMed ID: 26205255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fasudil Promotes α-Synuclein Clearance in an AAV-Mediated α-Synuclein Rat Model of Parkinson's Disease by Autophagy Activation.
    Yang YJ; Bu LL; Shen C; Ge JJ; He SJ; Yu HL; Tang YL; Jue Z; Sun YM; Yu WB; Zuo CT; Wu JJ; Wang J; Liu FT
    J Parkinsons Dis; 2020; 10(3):969-979. PubMed ID: 32568105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retina as a Model to Study In Vivo Transmission of α-Synuclein in the A53T Mouse Model of Parkinson's Disease.
    Mammadova N; Baron T; Verchère J; Greenlee JJ; Greenlee MHW
    Methods Mol Biol; 2021; 2224():75-85. PubMed ID: 33606207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.